

## **Aktuelle Publikationen von Mitarbeitern oder unter Beteiligung von Mitarbeitern der Klinik und Poliklinik für Psychiatrie und Psychotherapie im Jahr 2009**

### **Articles, Editorial Material, Letters, News Items, Notes und Reviews**

Alexopoulos P, Günther F, **Popp J, Jessen F**, Peters O, Wolf S, Kneib T, Kurz A, Richter-Schmidinger T, Lewczuk P, Bleich S, Wiltfang J, Kornhuber J. Plasma homocysteine and cerebrospinal fluid (CSF) neurodegeneration biomarkers in mild cognitive impairment (MCI) and dementia.  
*J Am Geriatr Soc.* 2009;57(4): 737-9 (Impact(2008)=3.805)

Bach JP, Oertel WH, Dodel R, **Jessen F**. Treatment of hypersexuality in Parkinson's disease with carbamazepine--a case report.  
*Mov Disord.* 2009;24(8): 1241-2 (Impact(2008)=3.898)

Backmund M, **Schütz C**, Meyer K, Edlin BR, Reimer J. The risk of emergency room treatment due to overdose in injection drug users.  
*J Addict Dis.* 2009;28(1): 68-73 (Impact(2008)=1.182)

Ball HA, Samaan Z, Brewster S, Craddock N, Gill M, Korszun A, **Maier W**, Middleton L, Mors O, Owen MJ, Perry J, Preisig M, Rice J, Rietschel M, Jones L, Jones I, Farmer AE, McGuffin P. Depression, migraine with aura and migraine without aura: their familiarity and interrelatedness.  
*Cephalalgia.* 2009;29(8): 848-54 (Impact(2008)=3.686)

Block W, Träber F, **von Widdern O, Metten M**, Schild H, **Maier W, Zobel A, Jessen F**. Proton MR spectroscopy of the hippocampus at 3 T in patients with unipolar major depressive disorder: correlates and predictors of treatment response.  
*Int J Neuropsychopharmacol.* 2009;12(3): 415-22 (Impact(2008)=4.378)

Brockmann H\*, **Zobel A\***, Joe A, Biermann K, Scheef L, **Schuhmacher A, von Widdern O, Metten M**, Biersack HJ, **Maier W**, Boecker H. The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression.  
*Psychiatry Res.* 2009;173(2): 107-12 (Impact(2008)=2.666)

\* contributed equally

Cohen MX, Axmacher N, Lenartz D, Elger CE, Sturm V, **Schläpfer TE**. Good vibrations: cross-frequency coupling in the human nucleus accumbens during reward processing.  
*J Cogn Neurosci.* 2009;21(5): 875-89 (Impact(2008)=4.867)

Cohen MX, Axmacher N, Lenartz D, Elger CE, Sturm V, **Schläpfer TE**. Neuroelectric signatures of reward learning and decision-making in the human nucleus accumbens.  
*Neuropsychopharmacology.* 2009;34(7): 1649-58 (Impact(2008)=6.835)

Cohen MX, Axmacher N, Lenartz D, Elger CE, Sturm V, **Schläpfer TE**. Nuclei accumbens phase synchrony predicts decision-making reversals following negative feedback.  
*J Neurosci.* 2009;29(23): 7591-8 (Impact(2008)=7.452)

Combarros O, van Duijn CM, Hammond N, Belbin O, Arias-Vásquez A, Cortina-Borja M, Lehmann MG, Aulchenko YS, Schuur M, **Kölsch H, Heun R**, Wilcock GK, Brown K, Kehoe PG, Harrison R, Coto E, Alvarez V, Deloukas P, Mateo I, Gwilliam R, Morgan K, Warden DR, Smith AD, Lehmann DJ. Replication by the Epistasis Project of the interaction between the genes for IL-6 and IL-10 in the risk of Alzheimer's disease.  
*J Neuroinflammation.* 2009;6: 22 (Impact(2008)=3.206)

Dobrusin M, Weitzman D, Levine J, Kremer I, Rietschel M, **Maier W**, Belmaker RH. The rate of consanguineous marriages among parents of schizophrenic patients in the Arab Bedouin population in

Southern Israel.

*World J Biol Psychiatry*. 2009;10(4): 334-6 (Impact(2008)=3.582)

Ehreke L, Luppä M, Luck T, Wiese B, Weyerer S, Eifflaender-Gorfer S, Weeg D, Olbrich J, van den Bussche H, Bachmann C, Eisele M, **Maier W, Jessen F, Wagner M**, Fuchs A, Pentzek M, Angermeyer MC, König HH, Riedel-Heller SG; AgeCoDe group. Is the clock drawing test appropriate for screening for mild cognitive impairment?--Results of the German study on Ageing, Cognition and Dementia in Primary Care Patients (AgeCoDe).

*Dement Geriatr Cogn Disord*. 2009;28(4): 365-72 (Impact(2008)=3.142)

Esslinger C\*, **Walter H\***, Kirsch P\*, **Erk S, Schnell K, Arnold C**, Haddad L, Mier D, **Opitz von Boberfeld C**, Raab K, Witt SH, Rietschel M, Cichon S, Meyer-Lindenberg A. Neural mechanisms of a genome-wide supported psychosis variant.

*Science*. 2009;324: 605 (Impact(2008)=28.103)

\* shared first authorship

Ganda C, Schwab SG, Amir N, Heriani H, Irmansyah I, Kusumawardhani A, Nasrun M, Widyawati I, **Maier W**, Wildenauer DB. A family-based association study of DNA sequence variants in GRM7 with schizophrenia in an Indonesian population.

*Int J Neuropsychopharmacol*. 2009;12(9): 1283-9 (Impact(2008)=4.378)

George MS, Padberg F, **Schläpfer TE**, O'Reardon JP, Fitzgerald PB, Nahas ZH, Marcolin MA. Controversy: repetitive transcranial magnetic stimulation or transcranial direct current stimulation shows efficacy in treating psychiatric diseases (depression, mania, schizophrenia, obsessive-compulsive disorder, panic, posttraumatic stress disorder).

*Brain Stimulat*. 2009;2(1): 14-21

Gerbershagen K, Gerbershagen HJ, Lutz J, **Cooper-Mahkorn D**, Wappler F, Limmroth V, Gerbershagen M. Pain prevalence and risk distribution among inpatients in a German teaching hospital.

*Clin J Pain*. 2009;25(5): 431-7 (Impact(2008)=2.889)

Goossens L, **Kukolja J, Onur OA**, Fink GR, **Maier W**, Griez E, Schruers K, **Hurlemann R**. Selective processing of social stimuli in the superficial amygdala.

*Hum Brain Mapp*. 2009;30(10): 3332-8 (Impact(2008)=5.395)

Gründer G, Aldenhoff J, Bergmann F, Eckermann G, **Maier W**, Möller HJ, Fritze J. Stellungnahme der Deutschen Gesellschaft für Psychiatrie, Psychotherapie und Psychotherapie (DGPPN) zu den "Empfehlungen der Arzneimittelkommission der deutschen Ärzteschaft zur Verordnung von benzodiazepinhaltigen Hypnotika".

*Nervenarzt*. 2009;80(2): 219-21 (Impact(2008)=0.814)

Günther U, Muders T, Wrigge H, **Popp J**, Andorfer U, Putensen C. Deutsche Kurzversion: Confusion Assessment Method for Intensive Care Unit zur routinemäßigen Kontrolle des Delirs auf der Intensivstation.

*Anästhesiologie und Intensivmedizin*. 2009;10: 592-600

Haasen C, Eiroa-Orosa FJ, Verthein U, Soyka M, **Dilig C**, Schäfer I, Reimer J. Effects of heroin-assisted treatment on alcohol consumption: findings of the German randomized controlled trial.

*Alcohol*. 2009;43(4): 259-64 (Impact(2008)=2.363)

Haenisch B, Linsel K, Brüss M, Gilsbach R, Propping P, Nöthen MM, **Rietschel M**, Fimmers R, **Maier W, Zobel A, Höfels S, Guttenthaler V**, Göthert M, Bönisch H. Association of major depression with rare functional variants in norepinephrine transporter and serotonin(1A) receptor genes.

*Am J Med Genet B Neuropsychiatr Genet*. 2009;150B(7): 1013-6 (Impact(2008)=3.932)

Hamshere ML, **Schulze TG**, Schumacher J, Corvin A, Owen MJ, Jamra RA, Propping P, **Maier W**, Orozco y Diaz G, Mayoral F, Rivas F, Jones I, Jones L, Kirov G, Gill M, Holmans PA, Nöthen MM,

Cichon S, **Rietschel M**, Craddock N. Mood-incongruent psychosis in bipolar disorder: conditional linkage analysis shows genome-wide suggestive linkage at 1q32.3, 7p13 and 20q13.31. *Bipolar Disord.* 2009;11(6): 610-20 (Impact(2008)=3.959)

Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, **Maier W**, **Jessen F**, **Schürmann B**, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frölich L, Hampel H, Hüll M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Mühleisen TW, Nöthen MM, Moebus S, Jöckel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. *Nat Genet.* 2009;41(10): 1088-93. Erratum in: *Nat Genet.* 2009;41(10): 1156 (Impact(2008)=30.259)

Hohoff C, Neumann A, Domschke K, Jacob C, **Maier W**, Fritze J, Bandelow B, Krakowitzky P, Rothermundt M, Arolt V, Deckert J. Association analysis of Rgs7 variants with panic disorder. *J Neural Transm.* 2009;116(11): 1523-8 (Impact(2008)=2.514)

Holmans PA, Riley B, Pulver AE, Owen MJ, Wildenauer DB, Gejman PV, Mowry BJ, Laurent C, Kendler KS, Nestadt G, Williams NM, Schwab SG, Sanders AR, Nertney D, Mallet J, Wormley B, Lasseter VK, O'Donovan MC, Duan J, Albus M, Alexander M, Godard S, Ribble R, Liang KY, Norton N, **Maier W**, Papadimitriou G, Walsh D, Jay M, O'Neill A, Lerer FB, Dikeos D, Crowe RR, Silverman JM, Levinson DF. Genomewide linkage scan of schizophrenia in a large multicenter pedigree sample using single nucleotide polymorphisms. *Mol Psychiatry.* 2009;14(8): 786-95 (Impact(2008)=12.537)

**Hong GS**, **Heun R**, **Jessen F**, **Popp J**, Hentschel F, Kelemen P, **Schulz A**, **Maier W**, **Kölsch H**. Gene variations in GSTM3 are a risk factor for Alzheimer's disease. *Neurobiol Aging.* 2009;30(5): 691-6 (Impact(2008)=5.959)

Huezo-Diaz P, Uher R, Smith R, Rietschel M, Henigsberg N, Marusic A, Mors O, **Maier W**, Hauser J, Souery D, Placentino A, **Zobel A**, Larsen ER, Czernski PM, Gupta B, Hoda F, Perroud N, Farmer A, Craig I, Aitchison KJ, McGuffin P. Moderation of antidepressant response by the serotonin transporter gene. *Br J Psychiatry.* 2009;195(1): 30-8 (Impact(2008)=5.077)

**Hurlemann R\***, **Schläpfer TE\***, Matusch A, **Reich H**, Shah NJ, Zilles K, **Maier W**, Bauer A. Reduced 5-HT(2A) receptor signaling following selective bilateral amygdala damage. *Soc Cogn Affect Neurosci.* 2009;4(1): 79-84

\* contributed equally

Indlekofer F, Piechatek M, **Daamen M**, **Glasmacher C**, Lieb R, Pfister H, Tucha O, Lange KW, Wittchen HU, **Schütz CG**. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. *J Psychopharmacol.* 2009;23(5): 495-509 (Impact(2008)=4.063)

Jäger M, Riedel M, Schmauss M, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, **Kühn KU**, Lemke MR, Rüter E, Buchkremer G, Gastpar M, Bottlender R, Strauss A, Möller HJ. Prediction of symptom remission in schizophrenia during inpatient treatment. *World J Biol Psychiatry.* 2009;10(4 Pt 2): 426-34 (Impact(2008)=3.582)

Jäger M, Schmauß M, Laux G, Pfeiffer H, Naber D, G Schmidt L, Gaebel W, Klosterkötter J, Heuser I, **Maier W**, Lemke MR, Degner D, Buchkremer G, Gastpar M, Möller HJ, Riedel M. Early improvement

as a predictor of remission and response in schizophrenia: results from a naturalistic study.  
*Eur Psychiatry*. 2009;24(8): 501-6 (Impact(2008)=2.433)

Janowitz D, Grabe HJ, Ruhrmann S, Ettelt S, **Buhtz F, Hochrein A, Schulze-Rauschenbach S**, Meyer K, Kraft S, Ferber C, Pukrop R, Freyberger HJ, Klosterkötter J, Falkai P, John U, **Maier W, Wagner M**. Early onset of obsessive-compulsive disorder and associated comorbidity.  
*Depress Anxiety*. 2009;26(11): 1012-7 (Impact(2008)=2.526)

**Jessen F**. Bildgebende Verfahren in der Diagnostik der Alzheimer Demenz.  
*Journal für Neurologie, Neurochirurgie und Psychiatrie*. 2009;3: 70-3

**Jessen F**. Diagnostik von Demenzerkrankungen.  
*Heilberufe*. 2009;61(6): 4

**Jessen F**. Diagnostische Schärfe des Mini-Mental-Status Tests - Wann ist der Einsatz in der Hausarztpraxis sinnvoll?  
*Info Neurologie & Psychiatrie*. 2009;6: 20-1

**Jessen F**. Prävention und Frühbehandlung von Demenzen.  
*Neuro Aktuell*. 2009;6: 32-5

**Jessen F**, Gür O, Block W, Ende G, Frölich L, Hammen T, Kornhuber J, Wiltfang J, Kucinski T, Jahn H, **Heun R, Maier W, Kölsch H**, Träber F. A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI.  
*Neurology*. 2009;72(20): 1735-40 (Impact(2008)=7.043)

**Jessen F, Maier W**, Spottke A, Deuschl G. S3-Leitlinie Demenzen: Eine integrative Leistung zwischen Neurologie und Psychiatrie/Psychotherapie.  
*MedReport*. 2009;44: 15

**Jessen F, Schuhmacher A, von Widdern O, Guttenthaler V, Höfels S, Suliman H**, Scheef L, Block W, Urbach H, **Maier W, Zobel A**. No association of the val66met polymorphism of the brain-derived neurotrophic factor with hippocampal volume in major depression.  
*Psychiatr Genet*. 2009;19(2): 99-101 (Impact(2008)=2.696)

**Kayser S, Bewernick B**, Axmacher N, **Schläpfer TE**. Magnetic seizure therapy of treatment-resistant depression in a patient with bipolar disorder.  
*J ECT*. 2009;25(2): 137-40 (Impact(2008)=0.974)

Kilts CD, Wade AG, Andersen HF, **Schläpfer TE**. Baseline severity of depression predicts antidepressant drug response relative to escitalopram.  
*Expert Opin Pharmacother*. 2009;10(6): 927-36 (Impact(2008)=2.077)

Kircher TJ, Thienel R, **Wagner M**, Reske M, Habel U, Kellermann T, **Frommann I, Schwab SG**, Wölwer W, von Wilmsdorf S, Braus DF, Schmitt A, Rapp A, Stöcker T, Shah J, Henn FA, Sauer H, Gaebel W, **Maier W**, Schneider F. Neuregulin 1 ICE-single nucleotide polymorphism in first episode schizophrenia correlates with cerebral activation in fronto-temporal areas.  
*Eur Arch Psychiatry Clin Neurosci*. 2009;259(2): 72-9 (Impact(2008)=2.852)

Klafki HW, Lewczuk P, Kamrowski-Kruck H, Maler JM, Müller K, Peters O, Heuser I, **Jessen F, Popp J**, Frölich L, Wolf S, Prinz B, Luckhaus C, Schröder J, Pantel J, Gertz HJ, **Kölsch H**, Müller BW, Esselmann H, Bibl M, Kornhuber J, Wiltfang J. Measurement of ERK 1/2 in CSF from patients with neuropsychiatric disorders and evidence for the presence of the activated form.  
*J Alzheimers Dis*. 2009;18(3): 613-22 (Impact(2008)=5.101)

Klingberg S, Wittorf A, Bechdorf A, Herrlich J, Kircher T, König HH, Müller B, Sartory G, **Wagner M**, Wiedemann G, Wölwer W, Buchkremer G. Psychotherapieforschung zur Kognitiven Verhaltenstherapie bei Positiv-Symptomen psychotischer Störungen.  
*Psychother Psychosom Med Psychol*. 2009;59(3-4): 141-8 (Impact(2008)=1.212)

Klotz L, Burgdorf S, Dani I, Saijo K, Flossdorf J, Hucke S, **Alferink J**, Novak N, Beyer M, Mayer G, Langhans B, Klockgether T, Waisman A, Eberl G, Schultze J, Famulok M, Kolanus W, Glass C, Kurts C, Knolle PA. The nuclear receptor PPAR gamma selectively inhibits Th17 differentiation in a T cell-intrinsic fashion and suppresses CNS autoimmunity.  
*J Exp Med.* 2009;206(10): 2079-89 (Impact(2008)=15.463)

Klotz L, Schmidt S, **Heun R**, Klockgether T, **Kölsch H**. Association of the PPAR gamma gene polymorphism Pro12Ala with delayed onset of multiple sclerosis.  
*Neurosci Lett.* 2009;449(1): 81-3 (Impact(2008)=2.200)

**Kölsch H**, **Jessen F**, Wiltfang J, Lewczuk P, Dichgans M, Teipel S, Kornhuber J, Frölich L, Heuser I, Peters O, Wiese B, Kaduszkiewicz H, van den Bussche H, Hüll M, Kurz M, Rütger E, Henn FA, **Maier W**. Association of SORL1 gene variants with Alzheimer's disease.  
*Brain Res.* 2009;1264: 1-6 (Impact(2008)=2.494)

**Kölsch H**, Lütjohann D, **Jessen F**, **Popp J**, Hentschel F, Kelemen P, Friedrichs S, **Maier W**, Heun R. RXRA gene variations influence Alzheimer's disease risk and cholesterol metabolism.  
*J Cell Mol Med.* 2009;13(3): 589-98 (Impact(2008)=5.114)

**Kölsch H**, Lütjohann D, **Jessen F**, **Popp J**, Hentschel F, Kelemen P, **Schmitz S**, **Maier W**, Heun R. CYP46A1 variants influence Alzheimer's disease risk and brain cholesterol metabolism.  
*Eur Psychiatry.* 2009;24(3): 183-90 (Impact(2008)=2.433)

**Kölsch H\***, **Wagner M\***, Bilkei-Gorzó A, Toliat MR, Pentzek M, Fuchs A, Kaduszkiewicz H, van den Bussche H, Riedel-Heller SG, Angermeyer MC, Weyerer S, Werle J, Bickel H, Mösch E, Wiese B, **Daerr M**, **Jessen F**, **Maier W**, Dichgans M. Gene polymorphisms in prodynorphin (PDYN) are associated with episodic memory in the elderly.  
*J Neural Transm.* 2009;116(7): 897-903 (Impact(2008)=2.514)

\* contributed equally

Kornhuber J, Schmidtke K, Frölich L, Pernecky R, Wolf S, Hampel H, **Jessen F**, Heuser I, Peters O, Weih M, Jahn H, Luckhaus C, Hüll M, Gertz HJ, Schröder J, Pantel J, Rienhoff O, Seuchter SA, Rütger E, Henn F, **Maier W**, Wiltfang J. Early and differential diagnosis of dementia and mild cognitive impairment. Design and cohort baseline characteristics of the German Dementia Competence Network.  
*Dement Geriatr Cogn Disord.* 2009;27(5): 404-17 (Impact(2008)=3.142)

Linden M, **Maier W**, Möller HJ, Sass H. Wissenschaft lebt von der Auseinandersetzung.  
*Nervenarzt.* 2009;80(11): 1341-2 (Impact(2008)=0.814)

Lisanby SH, Pallanti S, **Schläpfer TE**. FDA considers classification of ECT.  
*CNS Spectr.* 2009;14(12): 668-70 (Impact(2008)=1.974)

Luck T, Riedel-Heller SG, Wiese B, Stein J, Weyerer S, Werle J, Kaduszkiewicz H, **Wagner M**, Mösch E, Zimmermann T, **Maier W**, Bickel H, van den Bussche H, **Jessen F**, Fuchs A, Pentzek M; für die AgeCoDe Study Group. CERAD-NP-Testbatterie: Alters-, geschlechts- und bildungsspezifische Normen ausgewählter Subtests.  
*Z Gerontol Geriatr.* 2009;42(5): 372-84 (Impact(2008)=0.691)

**Maier W**. [Evidence-based medicine in diagnosis and therapy of depression].  
*MMW Fortschr Med.* 2009;151(13): 86-8

**Maier W**, Falkai P. Neues zur Diagnostik und Therapie schizophrener Psychosen.  
*Nervenarzt.* 2009;80(1): 5 (Impact(2008)=0.814)

Marziniak M, Kienzler C, Kühlenbäumer G, Sommer C, **Mössner R**. Functional gene variants of the serotonin-synthesizing enzyme tryptophan hydroxylase 2 in migraine.  
*J Neural Transm.* 2009;116(7): 815-9 (Impact(2008)=2.514)

Mauri MC, Turner M, Volonteri LS, Medori R, **Maier W**. Dosing patterns in Europe: efficacy and safety of risperidone long-acting injectable in doses of 25, 37.5 and 50 mg.  
*Int J Psychiatry Clin Pract.* 2009;13(1): 36-47 (Impact(2008)=0.410)

McCarthy SE, Makarov V, Kirov G, Addington AM, McClellan J, Yoon S, Perkins DO, Dickel DE, Kusenda M, Krastoshevsky O, Krause V, Kumar RA, Grozeva D, Malhotra D, Walsh T, Zackai EH, Kaplan P, Ganesh J, Krantz ID, Spinner NB, Roccanova P, Bhandari A, Pavon K, Lakshmi B, Leotta A, Kendall J, Lee YH, Vacic V, Gary S, Iakoucheva LM, Crow TJ, Christian SL, Lieberman JA, Stroup TS, Lehtimäki T, Puura K, Haldeman-Englert C, Pearl J, Goodell M, Willour VL, Derosse P, Steele J, Kassem L, Wolff J, Chitkara N, McMahon FJ, Malhotra AK, Potash JB, Schulze TG, Nöthen MM, Cichon S, **Rietschel M**, Leibenluft E, Kustanovich V, Lajonchere CM, Sutcliffe JS, Skuse D, Gill M, Gallagher L, Mendell NR; Wellcome Trust Case Control Consortium, Craddock N, Owen MJ, O'Donovan MC, Shaikh TH, Susser E, Delisi LE, Sullivan PF, Deutsch CK, Rapoport J, Levy DL, King MC, Sebat J. Microduplications of 16p11.2 are associated with schizophrenia.  
*Nat Genet.* 2009;41(11): 1223-7 (Impact(2008)=30.259)

**Mössner R, Maier W**, Rujescu D. Neue Erkenntnisse zur Genetik der Schizophrenie.  
*Nervenarzt.* 2009;80(1): 6, 8, 10-1 (Impact(2008)=0.814)

**Mössner R, Schuhmacher A, Kühn KU, Cvetanovska G**, Rujescu D, Zill P, **Quednow BB**, Rietschel M, Wölwer W, Gaebel W, **Wagner M, Maier W**. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia.  
*Pharmacogenet Genomics.* 2009;19(1): 91-4 (Impact(2008)=4.409)

**Müller S**. Enthemmt durch Tiefe Hirnstimulation.  
*Ärztliche Praxis Neurologie/Psychiatrie.* 2009;23(8): 30-1

**Müller S**. Magnetic fluid hyperthermia therapy for malignant brain tumours - an ethical discussion.  
*Nanomedicine: Nanotechnology, Biology and Medicine.* 2009;5(4): 387-93

Musshoff F, Lachenmeier K, **Lichtermann D**, Madea B. Cocaine and opiate concentrations in hair from subjects in a heroin maintenance program in comparison to a methadone substituted group.  
*Int J Legal Med.* 2009;123(5): 363-9 (Impact(2008)=2.574)

Ng MY, Levinson DF, Faraone SV, Suarez BK, DeLisi LE, Arinami T, Riley B, Paunio T, Pulver AE, Irmansyah, Holmans PA, Escamilla M, Wildenauer DB, Williams NM, Laurent C, Mowry BJ, Brzustowicz LM, Maziade M, Sklar P, Garver DL, Abecasis GR, Lerer B, Fallin MD, Gurling HM, Gejman PV, Lindholm E, Moises HW, Byerley W, Wijsman EM, Forabosco P, Tsuang MT, Hwu HG, Okazaki Y, Kendler KS, Wormley B, Fanous A, Walsh D, O'Neill FA, Peltonen L, Nestadt G, Lasseter VK, Liang KY, Papadimitriou GM, Dikeos DG, Schwab SG, Owen MJ, O'Donovan MC, Norton N, Hare E, Raventos H, Nicolini H, Albus M, **Maier W**, Nimgaonkar VL, Terenius L, Mallet J, Jay M, Godard S, Nertney D, Alexander M, Crowe RR, Silverman JM, Bassett AS, Roy MA, Mérette C, Pato CN, Pato MT, Roos JL, Kohn Y, Amann-Zalcenstein D, Kalsi G, McQuillin A, Curtis D, Brynjolfson J, Sigmundsson T, Petursson H, Sanders AR, Duan J, Jazin E, Myles-Worsley M, Karayiorgou M, Lewis CM. Meta-analysis of 32 genome-wide linkage studies of schizophrenia.  
*Mol Psychiatry.* 2009;14(8): 774-85 (Impact(2008)=12.537)

O'Donovan MC, Norton N, Williams H, Peirce T, Moskvina V, Nikolov I, Hamshere M, Carroll L, Georgieva L, Dwyer S, Holmans P, Marchini JL, Spencer CCA, Howie B, Leung H-T, Giegling I, Hartmann AM, Möller H-J, Morris DW, Shi Y, Feng G, Hoffmann P, Propping P, Vasilescu C, **Maier W**, Rietschel M, Zammit S, Schumacher J, Quinn EM, Schulze TG, Iwata N, Ikeda M, Darvasi A, Shifman S, He L, Duan J, Sanders AR, Levinson DF, Adolfsson R, Ösby U, Terenius L, Jönsson EG, Cichon S, Nöthen MM, Gill M, Corvin AP, Rujescu D, Gejman PV, Kirov G, Craddock N, Williams NM, Owen MJ. Molecular Genetics of Schizophrenia Collaboration. Analysis of 10 independent samples provides evidence for association between schizophrenia and a SNP flanking fibroblast growth factor receptor 2.  
*Mol Psychiatry.* 2009;14(1): 30-6 (Impact(2008)=12.537)

**Onur OA, Walter H, Schläpfer TE, Rehme AK, Schmidt C, Keyzers C, Maier W, Hurlemann R.** Noradrenergic enhancement of amygdala responses to fear. *Soc Cogn Affect Neurosci.* 2009;4(2): 119-26

Pentzek M, Fuchs A, Wiese B, **Cvetanovska-Pilashniku G, Haller F, Maier W**, Riedel-Heller SG, Angermeyer MC, Bickel H, Mösch E, Weyerer S, Werle J, van den Bussche H, Eisele M, Kaduszkiewicz H; AgeCoDe study group. General practitioners' judgment of their elderly patients' cognitive status. *J Gen Intern Med.* 2009;24(12): 1314-7 (Impact(2008)=2.720)

Pentzek M, Wollny A, Wiese B, **Jessen F, Haller F, Maier W**, Riedel-Heller SG, Angermeyer MC, Bickel H, Mösch E, Weyerer S, Werle J, Bachmann C, Zimmermann T, van den Bussche H, Abholz HH, Fuchs A, AgeCoDe Study Group. Apart from nihilism and stigma: what influences general practitioners' accuracy in identifying incident dementia? *Am J Geriatr Psychiatry.* 2009;17(11): 965-75 (Impact(2008)=4.022)

Perroud N, Aitchison KJ, Uher R, Smith R, Huezo-Diaz P, Marusic A, **Maier W**, Mors O, Placentino A, Henigsberg N, Rietschel M, Hauser J, Souery D, Kapelski P, Bonvicini C, **Zobel A**, Jorgensen L, Petrovic A, Kalember P, Schulze TG, Gupta B, Gray J, Lewis CM, Farmer AE, McGuffin P, Craig I. Genetic predictors of increase in suicidal ideation during antidepressant treatment in the GENDEP project. *Neuropsychopharmacology.* 2009;34(12): 2517-28 (Impact(2008)=6.835)

Perroud N, Uher R, Marusic A, Rietschel M, Mors O, Henigsberg N, Hauser J, **Maier W**, Souery D, Placentino A, Szczepankiewicz A, Jorgensen L, Strohmaier J, **Zobel A**, Giovannini C, Elkin A, Gunasinghe C, Gray J, Campbell D, Gupta B, Farmer AE, McGuffin P, Aitchison KJ. Suicidal ideation during treatment of depression with escitalopram and nortriptyline in Genome-Based Therapeutic Drugs for Depression (GENDEP): a clinical trial. *BMC Med.* 2009;7(1): 60 (Impact(2008)=3.276)

**Petrovsky N**, Schmechtig A, Flomen RH, Kumari V, Collier D, Makoff A, **Wagner M**, Ettinger U. CHRFAM7A copy number and 2-bp deletion polymorphisms and antisaccade performance. *Int J Neuropsychopharmacol.* 2009;12(2): 267-73 (Impact(2008)=4.378)

**Petrovsky N, Weiss-Motz F, Schulze-Rauschenbach S**, Lemke M, Hornung P, Ruhrmann S, Klosterkötter J, **Maier W**, Ettinger U, **Wagner M**. Antisaccade performance is related to genetic loading for schizophrenia. *J Psychiatr Res.* 2009;43(3): 291-7 (Impact(2008)=4.679)

Piechatzek M, Indlekofer F, **Daamen M, Glasmacher C**, Lieb R, Pfister H, Tucha O, Lange KW, Wittchen HU, **Schütz CG**. Is moderate substance use associated with altered executive functioning in a population-based sample of young adults? *Hum Psychopharmacol.* 2009;24(8): 650-65 (Impact(2008)=2.08)

**Popp J**, Bacher M, **Kölsch H**, Noelker C, Deuster O, Dodel R, **Jessen F**. Macrophage migration inhibitory factor in mild cognitive impairment and Alzheimer's disease. *J Psychiatr Res.* 2009;43(8): 749-53 (Impact(2008)=4.679)

**Popp J**, Lewczuk P, Linnebank M, **Cvetanovska G**, Smulders Y, **Kölsch H, Frommann I**, Kornhuber J, **Maier W, Jessen F**. Homocysteine metabolism and cerebrospinal fluid markers for Alzheimer's disease. *J Alzheimers Dis.* 2009;18(4): 819-28 (Impact(2008)=5.101)

**Popp J, Schaper K, Kölsch H, Cvetanovska G**, Rommel F, Klingmüller D, Dodel R, Wüllner U, **Jessen F**. CSF cortisol in Alzheimer's disease and mild cognitive impairment. *Neurobiol Aging.* 2009;30(3): 498-500 (Impact(2008)=5.959)

Poustka F, **Maier W**. Genetik der kognitiven Fähigkeiten in der Lebensspanne. *Nervenarzt.* 2009;80(11): 1312-21 (Impact(2008)=0.814)

Preibisch C, Lanfermann H, Wallenhorst T, **Walter H, Erk S**. Neuroanatomical correlates of visual field bias: a sensitive system for detecting potential threads?  
*Brain Res.* 2009;1263: 69-77 (Impact(2008)=2.494)

**Quednow BB**, Schmechtig A, Ettinger U, **Petrovsky N**, Collier DA, Vollenweider FX, **Wagner M**, Kumari V. Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study.  
*Biol Psychiatry.* 2009;66(6): 614-20 (Impact(2008)=8.672)

**Qureschie H**, Heun R, **Popp J, Jessen F, Maier W, Schmitz S**, Hentschel F, Kelemen P, **Kölsch H**. Association of CETP polymorphisms with the risk of vascular dementia and white matter lesions.  
*J Neural Transm.* 2009;116(4): 467-72 (Impact(2008)=2.514)

Rabins P, Appleby BS, Brandt J, DeLong MR, Dunn LB, Gabriëls L, Greenberg BD, Haber SN, Holtzheimer PE 3rd, Mari Z, Mayberg HS, McCann E, Mink SP, Rasmussen S, **Schläpfer TE**, Vawter DE, Vitek JL, Walkup J, Mathews DJ. Scientific and ethical issues related to deep brain stimulation for disorders of mood, behavior, and thought.  
*Arch Gen Psychiatry.* 2009;66(9): 931-7 (Impact(2008)=14.273)

**Rehme AK, Frommann I, Peters S, Block V, Bludau J, Quednow BB, Maier W, Schütz C, Wagner M**. Startle cue-reactivity differentiates between light and heavy smokers.  
*Addiction.* 2009;104(10): 1757-64 (Impact(2008)=4.244)

Rujescu D, Zill P, Rietschel M, **Maier W**. Genetik suizidalen Verhaltens.  
*Nervenheilkunde.* 2009;28(4): 211-6 (Impact(2008)=0.373)

Schäfer I\*, Hansen H\*, Schön G\*, **Maier W\***, **Höfels S\***, Altiner A\*, Fuchs A\*, Gerlach FM\*, Petersen JJ\*, Gensichen J\*, Schulz S\*, Riedel-Heller S\*, Luppä M\*, Weyerer S\*, Werle J\*, Bickel H\*, Barth K\*, König HH\*, Rudolph A\*, Wiese B, Prokein J\*, Bullinger M\*, von dem Knesebeck O\*, Eisele M\*, Kaduszkiewicz H\*, Wegscheider K\*, van den Bussche H\*. The German MultiCare-study: patterns of multimorbidity in primary health care - protocol of a prospective cohort study.  
*BMC Health Serv Res.* 2009;9(1): 145 (Impact(2008)=1.680)

\* equal contributors

Scheef L, Boecker H, **Daamen M**, Fehse U, Landsberg MW, **Granath DO**, Mechling H, Effenberg AO. Multimodal motion processing in area V5/MT: evidence from an artificial class of audio-visual events.  
*Brain Res.* 2009;1252: 94-104 (Impact(2008)=2.494)

Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Huff W, Heuser I, **Maier W**, Lemke MR, Rütther E, Buchkremer G, Gastpar M, Möller HJ, Riedel M. Defining and predicting functional outcome in schizophrenia and schizophrenia spectrum disorders.  
*Schizophr Res.* 2009;113(2-3): 210-7 (Impact(2008)=4.174)

Schennach-Wolff R, Jäger M, Seemüller F, Obermeier M, Messer T, Laux G, Pfeiffer H, Naber D, Schmidt LG, Gaebel W, Klosterkötter J, Heuser I, **Maier W**, Lemke MR, Rütther E, Klingberg S, Gastpar M, Möller HJ, Riedel M. Attitude towards adherence in patients with schizophrenia at discharge.  
*J Psychiatr Res.* 2009;43(16): 1294-301 (Impact(2008)=4.679)

**Schläpfer TE, Bewernick BH**. Deep brain stimulation for psychiatric disorders--state of the art.  
*Adv Tech Stand Neurosurg.* 2009;34: 37-57

**Schläpfer TE, Bewernick BH, Kayser S**, Sturm V, Lenartz D, Schnitzler A. Psychiatric Indications for the Use of Deep Brain Stimulation.  
*Akt Neurol.* 2009;36 Suppl: S24-6 (Impact(2008)=0.295)

Schmitz-Hübsch T\*, **Schläpfer TE\***, **Westheide J\***, von Falkenhausen M\*, **Cooper-Mahkorn D\***, **Maier W\***, **Kühn KU\***. Clozapine: acquittal of the usual suspect.  
*World J Biol Psychiatry*. 2009;10(4 Pt 3): 981-4 (Impact(2008)=3.582)

\* contributed equally

Schneider F, **Maier W**. Psychiatrie in der Lebensspanne.  
*Nervenarzt*. 2009;80(11): 1273-4 (Impact(2008)=0.814)

**Schuhmacher A**, **Mössner R**, **Quednow BB**, **Kühn KU**, **Wagner M**, **Cvetanovska G**, Rujescu D, Zill P, Möller HJ, Rietschel M, Franke P, Wölwer W, Gaebel W, **Maier W**. Influence of 5-HT<sub>3</sub> receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia.  
*Pharmacogenet Genomics*. 2009;19(11): 843-51 (Impact(2008)=4.409)

Schulze TG, Detera-Wadleigh SD, Akula N, Gupta A, Kassem L, Steele J, Pearl J, Strohmaier J, Breuer R, Schwarz M, Propping P, Nöthen MM, Cichon S, Schumacher J; NIMH Genetics Initiative Bipolar Disorder Consortium, **Rietschel M**, McMahon FJ. Two variants in Ankyrin 3 (ANK3) are independent genetic risk factors for bipolar disorder.  
*Mol Psychiatry*. 2009;14(5): 487-91 (Impact(2008)=12.537)

Stamelou M, Matusch A, Elmenhorst D, **Hurlemann R**, Eggert KM, Zilles K, Oertel WH, Höglinger GU, Bauer A. Nigrostriatal upregulation of 5-HT<sub>2A</sub> receptors correlates with motor dysfunction in progressive supranuclear palsy.  
*Mov Disord*. 2009;24(8): 1170-5 (Impact(2008)=3.898)

**Staudinger MR**, **Erk S**, Ablner B, **Walter H**. Cognitive reappraisal modulates expected value and prediction error encoding in the ventral striatum.  
*Neuroimage*. 2009;47(2): 713-21 (Impact(2008)=5.694)

Sullivan PF, de Geus EJ, Willemsen G, James MR, Smit JH, Zandbelt T, Arolt V, Baune BT, Blackwood D, Cichon S, Coventry WL, Domschke K, Farmer A, Fava M, Gordon SD, He Q, Heath AC, Heutink P, Holsboer F, Hoogendijk WJ, Hottenga JJ, Hu Y, Kohli M, Lin D, Lucae S, Macintyre DJ, **Maier W**, McGhee KA, McGuffin P, Montgomery GW, Muir WJ, Nolen WA, Nöthen MM, Perlis RH, Pirolo K, Posthuma D, Rietschel M, Rizzu P, Schosser A, Smit AB, Smoller JW, Tzeng JY, van Dyck R, Verhage M, Zitman FG, Martin NG, Wray NR, Boomsma DI, Penninx BW. Genome-wide association for major depressive disorder: a possible role for the presynaptic protein piccolo.  
*Mol Psychiatry*. 2009;14(4): 359-75 (Impact(2008)=12.537)

Treutlein J, Cichon S, Ridinger M, Wodarz N, Soyka M, Zill P, **Maier W**, **Mössner R**, Gaebel W, Dahmen N, Fehr C, Scherbaum N, Steffens M, Ludwig KU, Frank J, Wichmann HE, Schreiber S, Dragano N, Sommer WH, Leonardi-Essmann F, Lourdasamy A, Gebicke-Haerter P, Wienker TF, Sullivan PF, Nöthen MM, Kiefer F, Spanagel R, Mann K, Rietschel M. Genome-wide association study of alcohol dependence.  
*Arch Gen Psychiatry*. 2009;66(7): 773-84 (Impact(2008)=14.273)

Treutlein J, Mühleisen TW, Frank J, Mattheisen M, Herms S, Ludwig KU, Treutlein T, Schmael C, Strohmaier J, Bösshenz KV, Breuer R, Paul T, Witt SH, Schulze TG, Schlösser RG, Nenadic I, Sauer H, Becker T, **Maier W**, Cichon S, Nöthen MM, Rietschel M. Dissection of phenotype reveals possible association between schizophrenia and Glutamate Receptor Delta 1 (GRID1) gene promoter.  
*Schizophr Res*. 2009;111(1-3): 123-30 (Impact(2008)=4.174)

Uher R, Farmer A, Henigsberg N, Rietschel M, Mors O, **Maier W**, Kozel D, Hauser J, Souery D, Placentino A, Strohmaier J, Perroud N, **Zobel A**, Rajewska-Rager A, Dernovsek MZ, Larsen ER, Kalember P, Giovannini C, Barreto M, McGuffin P, Aitchison KJ. Adverse reactions to antidepressants.  
*Br J Psychiatry*. 2009;195(3): 202-10 (Impact(2008)=5.077)

Uher R, Huezo-Diaz P, Perroud N, Smith R, Rietschel M, Mors O, Hauser J, **Maier W**, Kozel D, Henigsberg N, Barreto M, Placentino A, Dernovsek MZ, Schulze TG, Kalember P, **Zobel A**, Czerski

PM, Larsen ER, Souery D, Giovannini C, Gray JM, Lewis CM, Farmer A, Aitchison KJ, McGuffin P, Craig I. Genetic predictors of response to antidepressants in the GENDEP project. *Pharmacogenomics J.* 2009;9(4): 225-33 (Impact(2008)=5.435)

Uher R, **Maier W**, Hauser J, Marusic A, Schmael C, Mors O, Henigsberg N, Souery D, Placentino A, Rietschel M, **Zobel A**, Dmitrzak-Weglarczyk M, Petrovic A, Jorgensen L, Kalember P, Giovannini C, Barreto M, Elkin A, Landau S, Farmer A, Aitchison KJ, McGuffin P. Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression. *Br J Psychiatry.* 2009;194: 252-9 (Impact(2008)=5.077)

Uher R, Mors O, Hauser J, Rietschel M, **Maier W**, Kozel D, Henigsberg N, Souery D, Placentino A, Perroud N, Dernovsek MZ, Strohmaier J, Larsen ER, **Zobel A**, Leszczynska-Rodziewicz A, Kalember P, Pedrini L, Linotte S, Gunasinghe C, Aitchison KJ, McGuffin P, Farmer A. Body weight as a predictor of antidepressant efficacy in the GENDEP project. *J Affect Disord.* 2009;118(1-3): 147-54 (Impact(2008)=3.271)

Vasic N, **Walter H**, Sambataro F, Wolf RC. Aberrant functional connectivity of dorsolateral prefrontal and cingulate networks in patients with major depression during working memory processing. *Psychol Med.* 2009;39(6): 977-87 (Impact(2008)=4.718)

Wade AG, **Schläpfer TE**, Andersen HF, Kilts CD. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). *J Psychiatr Res.* 2009;43(5): 568-75 (Impact(2008)=4.679)

**Walter H**, Berger M, **Schnell K**. Neuropsychotherapy: conceptual, empirical and neuroethical issues. *Eur Arch Psychiatry Clin Neurosci.* 2009;259 Suppl 2: S173-82 (Impact(2008)=2.852)

**Walter H**, Ciaramidaro A, Adenzato M, Vasic N, Ardito RB, **Erk S**, Bara BG. Dysfunction of the social brain in schizophrenia is modulated by intention type: an fMRI study. *Soc Cogn Affect Neurosci.* 2009;4(2): 166-76

**Walter H**, Kalckreuth A, **Schardt D**, Stephan A, Goschke T, **Erk S**. The temporal dynamics of voluntary emotion regulation: immediate and delayed neural aftereffects. *PLoS ONE.* 2009;4(8): e6726

**Walter H**, Kammerer H, Frasch K, Spitzer M, Abler B. Altered reward functions in patients on atypical antipsychotic medication in line with the revised dopamine hypothesis of schizophrenia. *Psychopharmacology (Berl).* 2009;206(1): 121-32 (Impact(2008)=3.676)

Weyerer S, Schäufele M, Eifflaender-Gorfer S, Köhler L, **Maier W**, **Haller F**, **Cvetanovska-Pilashiniku G**, Pentzek M, Fuchs A, van den Bussche H, Zimmermann T, Eisele M, Bickel H, Mösch E, Wiese B, Angermeyer MC, Riedel-Heller SG; for the German AgeCoDe Study group. Further members of the German AgeCoDe Study group. Heinz-Harald Abholz, Cadja Bachmann, Wolfgang Blank, Michaela Buchwald, Mirjam Colditz, **Moritz Daerr**, **Frank Jessen**, Sven Heinrich, Hanna Kaduszkiewicz, Teresa Kaufeler, Hans-Helmut König, Tobias Luck, Melanie Lippa, Manfred Mayer, Julia Olbrich, Heinz-Peter Romberg, Anja Rudolph, **Melanie Sauder**, Britta Schürmann, **Michael Wagner**, Jochen Werle, Anja Wollny. (German Study on Ageing, Cognition, Dementia in Primary Care Patients). At-risk alcohol drinking in primary care patients aged 75 years and older. *Int J Geriatr Psychiatry.* 2009;24(12): 1376-85 (Impact(2008)=2.128)

Wittfoth M, **Schardt DM**, Fahle M, Herrmann M. How the brain resolves high conflict situations: double conflict involvement of dorsolateral prefrontal cortex. *Neuroimage.* 2009;44(3): 1201-9 (Impact(2008)=5.694)

Wittorf A, Jakobi U, Bechdorf A, Müller B, Sartory G, **Wagner M**, Wiedemann G, Wölwer W, Herrlich J, Buchkremer G, Klingberg S. The influence of baseline symptoms and insight on the therapeutic alliance early in the treatment of schizophrenia. *Eur Psychiatry.* 2009;24(4): 259-67 (Impact(2008)=2.433)

Wobrock T, Gruber O, Schneider-Axmann T, Wölwer W, Gaebel W, Riesbeck M, **Maier W**, Klosterkötter J, Schneider F, Buchkremer G, Möller HJ, Schmitt A, Bender S, Schlösser R, Falkai P. Internal capsule size associated with outcome in first-episode schizophrenia. *Eur Arch Psychiatry Clin Neurosci*. 2009;259(5): 278-83 (Impact(2008)=2.852)

Wolf RC, Vasic N, Sambataro F, Höse A, Frasch K, Schmid M, **Walter H**. Temporally anticorrelated brain networks during working memory performance reveal aberrant prefrontal and hippocampal connectivity in patients with schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry*. 2009;33(8): 1464-73 (Impact(2008)=2.638)

### **Bücher und Buchbeiträge**

**Jessen F** (2009) Genetik. In: Mahlberg R, Gutzmann H (Hrsg.) Diagnostik und Therapie von Demenzerkrankungen. Deutscher Ärzte-Verlag, Köln (157-160).

**Jessen F** (2009) Liquordiagnostik. In: Mahlberg R, Gutzmann H (Hrsg.) Diagnostik und Therapie von Demenzerkrankungen. Deutscher Ärzte-Verlag, Köln (153-156).

**Maier W**, Schulz JB, Weggen S, Wolf S (2009) Alzheimer & Demenzen verstehen: Diagnose, Behandlung, Alltag, Betreuung. Trias, Stuttgart.

**Müller S** (2009) BIID - Under which circumstances would be amputations of healthy limbs ethically justified? In: Stirn A, Oddo S, Thiel A (Eds.) Body Integrity Identity Disorder: psychological, neurobiological, ethical and legal aspects. Pabst, Lengerich (109-123).

**Müller S** (2009) Dilemmata bei der Behandlung von Hirntumoren am Beispiel von Akustikusneurinomen. In: Müller O, Clausen J, Maio G (Hrsg.) Das technisierte Gehirn. Ändern die aktuellen Neurotechnologien das menschliche Selbstverständnis? Mentis Verlag, Paderborn (187-217).

**Müller S** (2009) Ist Cognitive Enhancement zur Steigerung der Intelligenz ethisch geboten? Diskussion utilitaristischer und idealistischer Argumente. In: Schöne-Seifert B, Talbot D, Opolka U, Ach J (Hrsg.) Neuro-Enhancement. Ethik vor neuen Herausforderungen. Mentis Verlag, Paderborn (107-139).

**Müller S**, Groß D (2009) Akzeptanz von Leistungsbegrenzungen im Gesundheitswesen: Strategien, Kriterien und Finanzierungsmodelle unter Berücksichtigung ethischer Aspekte. In: Böcken J, Braun B, Amhof R (Hrsg.) Gesundheitsmonitor 2009: Gesundheitsversorgung und Gestaltungsoptionen aus der Perspektive der Bevölkerung. Bertelsmann, Gütersloh (258-279).

**Müller S**, Zaracko A, Groß D, Schmitz D (2009) Chancen und Risiken der Neurowissenschaften. Lehmanns, Berlin.

**Schläpfer TE, Bewernick BH** (2009) Deep brain stimulation: method, indications, locations and efficacy. In: Swartz C (ed.) Electroconvulsive therapy and neuromodulation. Cambridge University Press, Cambridge, MA.

**Schleim S**, Spranger T, **Walter H** (Hrsg.) (2009) Von der Neuroethik zum Neurorecht? Der Beginn einer neuen Debatte. Vandenhoeck & Ruprecht, Göttingen.

**Schleim S**, Spranger T, **Walter H** (2009) Von der Neuroethik zum Neurorecht? In: **Schleim S**, Spranger T, **Walter H** (Hrsg.) Von der Neuroethik zum Neurorecht? Der Beginn einer neuen Debatte. Vandenhoeck & Ruprecht, Göttingen (7-21).

**Walter H** (2009) Hirnforschung. In: Bohlken E, Thies C (Hrsg.) Handbuch Anthropologie. Der Mensch zwischen Natur, Kultur und Technik. Metzler, Stuttgart (137-146).

**Walter H** (2009) Was können wir messen? In: **Schleim S**, Spranger T, **Walter H** (Hrsg.) Von der Neuroethik zum Neurorecht? Der Beginn einer neuen Debatte. Vandenhoeck & Ruprecht, Göttingen (67-103).

**Walter H, Erk S** (2009) Seh' ich da was, was Du nicht siehst? Methoden, Möglichkeiten und Mängel des Neuroimaging. In: Spitzer M, Bertram W (Hrsg.) Hirnforschung für Neu(ro)gierige. Braintertainment 2.0. Schattauer, Stuttgart (185-206).